AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

HUTCHMED (China) Limited (HCM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

15.32

0.49 (3.30%)

At close: Feb 20, 2025, 3:59 PM

15.33

0.07%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	15.24
Market Cap	2.67B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.25
PE Ratio (ttm)	-61.28
Forward PE	n/a
Analyst	Hold

Ask	15.6
Volume	93,553
Avg. Volume (20D)	75,647
Open	15.25
Previous Close	14.83
Day's Range	15.32 - 15.60
52-Week Range	12.84 - 21.92
Beta	undefined

About HCM

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for ...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Mar 16, 2016

Employees 1,970

Stock Exchange NASDAQ

Ticker Symbol HCM

Website https://www.hutch-med.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for HCM stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 24.02% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+4.65%

HUTCHMED shares are trading higher after the compa... Unlock content with Pro Subscription

4 months ago

+5.32%

HUTCHMED shares are trading higher after the company announced high-level results from the SAVANNAH Phase II trial.

News

1 day ago · zacks.com

HUTCHMED (HCM) Upgraded to Buy: Here's Why

HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 day ago · zacks.com

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positi...

1 month ago · benzinga.com

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

On Wednesday, Hutchmed (China) Limited HCM entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 ...

1 month ago · reuters.com

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivo...

1 month ago · seekingalpha.com

Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)

I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps ...